Bairactaris C, Demakopoulos N, Tripsianis G, Sioka C, Farmakiotis D, Vadikolias K, Heliopoulos I, Georgoulias P, Tsougos I, Papanastasiou I, Piperidou C
Department of Neurology, 417 NIMTS Hospital, Athens, Greece.
J Clin Neurosci. 2009 Feb;16(2):246-52. doi: 10.1016/j.jocn.2008.01.020. Epub 2008 Dec 20.
To assess the impact of I-123 ioflupane single photon emission computed tomography (SPECT) imaging on classifying patients with striatal dopaminergic deficits. Sixty-one patients with an initial diagnosis of parkinsonism or uncertain tremor disorder were screened and followed-up for one year. All patients were re-examined by two neurologists at our centre and were classified as having neurodegenerative or non-neurodegenerative disorders. Patients underwent I-123 ioflupane SPECT imaging. SPECT studies were blindly evaluated and classified as normal or abnormal (indicative of neurodegenerative disorders). The overall agreement of the SPECT imaging results with the initial classification was 65.6% (kappa=0.229, p=0.074) but was 90.2% (kappa=0.782, p<0.001) with the classification of the neurologists at our centre. I-123 ioflupane SPECT imaging is a valuable method in the evaluation of patients presenting clinically with uncertain parkinsonian syndromes or for whom diagnostic doubt exists.
评估I-123碘氟潘单光子发射计算机断层扫描（SPECT）成像对纹状体多巴胺能缺陷患者进行分类的影响。对61例初步诊断为帕金森症或震颤障碍不明确的患者进行筛查并随访一年。所有患者均在本中心由两名神经科医生重新检查，并被分类为患有神经退行性或非神经退行性疾病。患者接受I-123碘氟潘SPECT成像。SPECT研究由盲法评估，并分类为正常或异常（提示神经退行性疾病）。SPECT成像结果与初始分类的总体一致性为65.6%（kappa=0.229，p=0.074），但与本中心神经科医生的分类一致性为90.2%（kappa=0.782，p<0.001）。I-123碘氟潘SPECT成像在评估临床上表现为帕金森综合征不明确或存在诊断疑问的患者时是一种有价值的方法。
